ABT-288

DB15192InvestigationalSmall molecule

ABT-288 is under investigation in clinical trial NCT01018875 (Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease).

Mechanism: Pharmacologically active on Histamine H3 receptor
Curator reviewed
Formula / weight: C₂₃H₂₄N₄O · 372.472 g/mol (avg)
Code names: ABT-288

Resolves to

Compound

UNII5MEI1M3NHHCAS948845-91-8

Structure

InChIKeyGNIRITULTPTAQW-KNQAVFIVSA-NSMILESCN1C[C@H]2CCN([C@H]2C1)C1=CC=C(C=C1)C1=CC=C(C=C1)N1N=CC=CC1=O

Targets

Q9Y5N1HRH3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

30Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with ABT-288, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account